SCHEMBL2199358

SCHEMBL2199358

Cc1nn(-c2cccc(OC(F)(F)F)c2)c(C)c1C(=O)N1CCC(N2CCC(C)C2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.49
TP53 P04637 1/20 0.42
NOTUM Q6P988 1/20 0.41
SCN9A Q15858 2/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
HSD11B1 P28845 1/20 0.40
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCKAR P32238 1/20 0.39
MGLL Q99685 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPY5R Q15761 1/20 0.38
EPHX2 P34913 1/20 0.37
MAPK7 Q13164 1/20 0.37
SPR P35270 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201602 0.92 SCN9A (0.40) KMT2ATP53NOTUMSCN9ASCN10A
SCHEMBL2201084 0.91 KMT2A (0.49) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2201088 0.91 KMT2A (0.49) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2202064 0.91 KMT2A (0.49) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2203158 0.90 KMT2A (0.51) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2201907 0.89 KMT2A (0.52) KMT2ANOTUMSCN9AHSD11B1MAPT
SCHEMBL2200707 0.89 KMT2A (0.52) KMT2AHSD11B1MAPTRAB9ANPSR1
SCHEMBL2200867 0.88 KMT2A (0.47) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2201420 0.88 KMT2A (0.47) KMT2ANOTUMSCN9ASCN10AHSD11B1
SCHEMBL2201606 0.88 KMT2A (0.47) KMT2ANOTUMSCN9ASCN10AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 KMT2A 4057/4885TP53 3028/4885NOTUM 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.